1. Academic Validation
  2. Computational research of mTORC1 inhibitor on cerebral ischemia-reperfusion injury

Computational research of mTORC1 inhibitor on cerebral ischemia-reperfusion injury

  • Aging (Albany NY). 2021 Aug 3;13(15):19598-19613. doi: 10.18632/aging.203371.
Hui Li 1 Wenzhuo Yang 2 Zhenhua Wang 2 Xu Wang 1 Yulei Hao 1 Jianxin Xi 2 Han Lu 2 Zhishan Du 2 Jiachun Feng 1 Bao Zhang 3 Di Ma 1
Affiliations

Affiliations

  • 1 Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China.
  • 2 Clinical College, Jilin University, Changchun, China.
  • 3 Department of Urology Surgery, Aerospace Center Hospital, Beijing, China.
Abstract

Ischemic stroke contributes to more than 80% of all strokes and has the four characteristics of high prevalence, high disability, high mortality, and high recurrence. Stroke is a preventable and controllable disease. In addition to controlling the primary disease, effective prevention and control measures need to be given to the occurrence and development of stroke. With the development and progress of modern treatment methods for ischemic stroke, the mortality and disability rate have decreased significantly. At present, the main treatment methods for ischemic stroke include thrombolysis, thrombus removal at the ultra-early stage, and treatment of improving collateral circulation in the acute phase. However, the ultra-early and early blood reperfusion involves reperfusion injury, which will cause secondary nerve damage, which is called cerebral ischemia/reperfusion injury (CIRI). Studies have found that Autophagy is involved in the entire process of CIRI and can reduce the damage of CIRI. The mammalian target of Rapamycin (mTORC1) is the primary signal pathway regulating Autophagy. And the mTORC1 Inhibitor, Rapamycin, has been proved to exert neuroprotective effects in the ultra-early and early cerebral ischemia-reperfusion. Therefore, screening and designing mTORC1 inhibitors is very important to control reperfusion injury and reduce neuronal death and Apoptosis. In this research, plenty of computer-assisted was applied to virtually screen and select potential mTORC1's inhibitors. We used Libdock to screen the structure and performed toxicity predictions, ADME (absorption, distribution, metabolism, excretion) to predict small molecules' pharmacological and toxicological properties. To assess the binding mechanism and affinity between the mTORC1 dimer and the ligand, molecular docking was performed. Then, the pharmacophore of small molecules in the docking conformation with the protein was supplemented by Schrodinger. Additionally, molecular dynamics simulations were conducted to assess if the ligand-receptor complex was stable in a natural environment. Furthermore, an experiment was performed to verify the inhibitory effect of compound 1 and compound 2 on mTOR protein. All in all, the study provides a hand of candidate drugs as well as pharmacological properties, which can play an essential role in mTORC1 inhibitors.

Keywords

autophagy; cerebral ischemia/reperfusion injury (CIRI); mTORC1 inhibitors; the mammalian target of rapamycin (mTORC1).

Figures
Products